Belzutifan significantly delays progression of advanced kidney cancer after other treatments have failed
Kidney cancers often have mutations in a gene called the von Hippel-Lindau [...]
Health-related quality of life with lenvatinib in combination with everolimus
Maintaining good health-related quality of life is important for all [...]
Can adjuvant everolimus prevent recurrence following surgery?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Telaglenastat plus everolimus in advanced kidney cancer
This phase 2 clinical trial (ENTRATA) looked at how safe [...]
Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer
This phase 1 clinical trial looked at the safety, tolerability, [...]
ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
Lenvatinib plus everolimus for non clear cell kidney cancer
Treating non-clear cell renal cell carcinoma (RCC) is challenging because [...]
Everolimus and bevacizumab for advanced papillary kidney cancer
In this phase 2 clinical trial, a combination of everolimus [...]
Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer
A new combination of vorolanib, a tyrosine kinase inhibitor plus [...]
ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
